ZA201304235B - Oprf/i agents and their use in hospitalized and other patients - Google Patents

Oprf/i agents and their use in hospitalized and other patients

Info

Publication number
ZA201304235B
ZA201304235B ZA2013/04235A ZA201304235A ZA201304235B ZA 201304235 B ZA201304235 B ZA 201304235B ZA 2013/04235 A ZA2013/04235 A ZA 2013/04235A ZA 201304235 A ZA201304235 A ZA 201304235A ZA 201304235 B ZA201304235 B ZA 201304235B
Authority
ZA
South Africa
Prior art keywords
oprf
hospitalized
patients
agents
Prior art date
Application number
ZA2013/04235A
Other languages
English (en)
Inventor
Christoph Klade
Robert Schlegl
Kerstin Westritschnig
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Publication of ZA201304235B publication Critical patent/ZA201304235B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2013/04235A 2010-12-23 2013-06-10 Oprf/i agents and their use in hospitalized and other patients ZA201304235B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061426760P 2010-12-23 2010-12-23
PCT/EP2011/054127 WO2012084272A1 (en) 2010-12-23 2011-03-18 Oprf/i agents and their use in hospitalized and other patients

Publications (1)

Publication Number Publication Date
ZA201304235B true ZA201304235B (en) 2014-09-25

Family

ID=44210049

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/04235A ZA201304235B (en) 2010-12-23 2013-06-10 Oprf/i agents and their use in hospitalized and other patients

Country Status (11)

Country Link
US (1) US20130266575A1 (enExample)
EP (1) EP2655402A1 (enExample)
JP (2) JP5893640B2 (enExample)
KR (1) KR20130133212A (enExample)
CN (1) CN103270047A (enExample)
AU (1) AU2011348396A1 (enExample)
BR (1) BR112013016254A2 (enExample)
CA (1) CA2822684A1 (enExample)
MX (1) MX2013007146A (enExample)
WO (1) WO2012084272A1 (enExample)
ZA (1) ZA201304235B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201706671WA (en) 2012-11-30 2017-09-28 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
CN103983793A (zh) * 2014-05-29 2014-08-13 上海理工大学 一种含丽春红的蛋白质芯片点样缓冲液及其制备方法
EA201790489A1 (ru) * 2014-08-29 2017-08-31 Сорренто Терапьютикс, Инк. ТЕРАПЕВТИЧЕСКИЕ СРЕДСТВА НА ОСНОВЕ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ OprF И OprI
US10344078B2 (en) 2015-05-01 2019-07-09 Inhibrx, Inc. Type III secretion system targeting molecules
WO2016193402A1 (en) 2015-06-03 2016-12-08 Valneva Austria Gmbh Pseudomonas vaccine
SG10201912410TA (en) 2015-07-16 2020-02-27 Inhibrx Inc Multivalent and multispecific dr5-binding fusion proteins
FR3099160B1 (fr) * 2019-07-23 2022-05-06 Univ Grenoble Alpes Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
CN117222740A (zh) * 2022-06-07 2023-12-12 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗
CN116251178A (zh) * 2023-03-28 2023-06-13 吉林农业大学 一种铜绿假单胞菌疫苗及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494672A (en) * 1989-04-28 1996-02-27 S.P.I. Synthetic Peptides Incorporated Pseudomonas peptide composition and method
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
EP0717106B1 (en) * 1994-12-16 2000-03-15 Chiron Behring Gmbh & Co. Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
JP2005501889A (ja) * 2001-09-03 2005-01-20 アンビクス パテンツ−ライセンシーズ アーゲー マクロライド系抗生物質を用いる緑膿菌感染症の治療法
ES2431318T3 (es) * 2001-11-13 2013-11-26 Id Biomedical Corporation Polipéptidos de Pseudomonas aeruginosa
BRPI0406800B8 (pt) * 2003-01-15 2021-05-25 Chugai Seiyaku Kk Chugai Pharmaceutical Co Ltd "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso
EP1623229A2 (en) 2003-05-15 2006-02-08 Cytos Biotechnology AG Selection of b cells with specificity of interest: method of preparation and use
GB0410958D0 (en) * 2004-05-15 2004-06-16 Haptogen Ltd Methods for reducing biofilm formation in infectious bacteria
BRPI0517200A (pt) * 2004-12-17 2008-09-30 Venus Remedies Ltd combinações de antibióticos, processos de preparação de uma combinação de antibióticos e método de tratamento
EP1921142A1 (en) 2006-11-07 2008-05-14 Cytos Biotechnology AG Selection of human monoclonal antibodies by eukaryotic cell display
SG10201706671WA (en) * 2012-11-30 2017-09-28 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations

Also Published As

Publication number Publication date
WO2012084272A1 (en) 2012-06-28
CN103270047A (zh) 2013-08-28
JP2014504297A (ja) 2014-02-20
BR112013016254A2 (pt) 2017-07-11
AU2011348396A2 (en) 2013-07-11
MX2013007146A (es) 2013-11-01
CA2822684A1 (en) 2012-06-28
KR20130133212A (ko) 2013-12-06
JP5893640B2 (ja) 2016-03-23
AU2011348396A1 (en) 2013-07-04
US20130266575A1 (en) 2013-10-10
JP2016147867A (ja) 2016-08-18
EP2655402A1 (en) 2013-10-30

Similar Documents

Publication Publication Date Title
IL221511A (en) Arilatriazolones associated with bis aryl and their use
IL249669A0 (en) Converted 5-fluoro-1h-pyrazolopyridines and their use
ZA201208173B (en) Peptices and their use
PT2592933T (pt) Inibidores de mif e suas utilizações
EP2552953A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
ZA201304235B (en) Oprf/i agents and their use in hospitalized and other patients
ZA201208948B (en) Modified beta-lactamases and methods and uses related thereto
ZA201303773B (en) Compounds and their use
EP2563131A4 (en) PESTICIDAL COMPOSITION AND USE THEREOF
PL2521445T3 (pl) Preparat i jego zastosowanie
ZA201207242B (en) Pesticidal composition and its use
PL2563133T3 (pl) Kompozycja szkodnikobójcza i jej zastosowanie
GB0920258D0 (en) New medical agents and use thereof
SI2552440T1 (sl) Nove kombinacije in uporaba
PL2563134T3 (pl) Kompozycja szkodnikobójcza i jej zastosowanie
PL2648715T3 (pl) Mieszaniny karnozyny-kwasu hialuronowego i ich zastosowanie
PT2563806E (pt) Leucolectinas humanas e suas utilizações
GB201008286D0 (en) Device and use
HK1191024A (en) Oprf/i agents and their use in hospitalized and other patients
GB201005826D0 (en) New compositions and their use
AU335567S (en) Combination patient education and storage article
GB201020848D0 (en) Compounds and their use
GB201005511D0 (en) Compounds and their use
GB201000307D0 (en) Compounds and their use
GB201000308D0 (en) Compounds and their use